Seminars in Oncology
Volume 34, Issue 6 , Pages 498-508, December 2007

Surgery and Sentinel Lymph Node Biopsy

  • Mark B. Faries

      Affiliations

    • Corresponding Author InformationAddress correspondence to Mark B. Faries, MD, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404.
  • ,
  • Donald L. Morton

Division of Surgical Oncology and the Roy E. Coats Research Laboratories, John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, CA.

In patients with melanoma, surgery is pivotal not only for the primary tumor but also for regional and often distant metastases. The minimally invasive technique of sentinel node (SN) biopsy has become standard for detection of occult regional node metastasis in patients with intermediate-thickness primary melanoma; in these patients it has a central role in determining prognosis and a significant impact on survival when biopsy results are positive. Its role in thin melanoma remains under evaluation. The regional tumor-draining SN also is a useful model for studies of melanoma-induced immunosuppression. Although completion lymphadenectomy remains the standard of care for patients with SN metastasis, results of ongoing phase III trials will indicate whether SN biopsy without further lymph node surgery is adequate therapy for certain patients with minimal regional node disease.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by Grant No. CA29605 from the National Cancer Institute and by funding from the Amyx Foundation, Inc (Boise, ID), the Wayne and Gladys Valley Foundation (Oakland, CA), and from Mr and Mrs Louis Johnson, (Stanfield, AZ).

PII: S0093-7754(07)00185-6

doi:10.1053/j.seminoncol.2007.09.010

Seminars in Oncology
Volume 34, Issue 6 , Pages 498-508, December 2007